好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Health Literacy and Medication Awareness in Outpatient Neurology
Neurologic 好色先生
P04 - (-)
246
BACKGROUND: Low HL is common and is associated with poorer disease control and higher mortality rates in numerous conditions. However, HL has yet to be adequately studied in outpatient neurology.
DESIGN/METHODS: Cross-sectional study of non-demented adults presenting to an academic neurology clinic at the University of Pennsylvania. Subjects were administered a questionnaire including demographics, medications, comorbidities, Mini-Mental Status Examination (MMSE) and the short Test of Functional Health Literacy in Adults (TOFHLA). Physician-documented diagnoses and medications were abstracted from the medical record. Based on TOFHLA score, individuals were categorized as having low or adequate HL. Logistic regression was performed to determine factors independently associated with HL.
RESULTS: 201 subjects (mean age 46.8 years (SD 15); 52.7% female; 51.7% African American) were surveyed. 25.9% had epilepsy, 18.4% Multiple Sclerosis, and 15.4% stroke. 20.5% had low HL. 26% were unable to name any of their medications, and 48.5% of subjects correctly identified <75%. In a multivariate regression model controlling for age and race, the following predicted low HL: male gender (OR 2.81; 95% CI 1.08-7.30), lower levels of education (OR 1.82; 1.15-2.89), each one-point decrease in MMSE (OR 1.40, 1.15-1.71), Medicaid or Medicare compared to self-pay or private insurance (OR 2.96, 1.05-8.38), diagnosis of stroke (OR 13.03, 1.36-124.58), and diagnosis of epilepsy (OR 12.65, 1.28-124.76).
CONCLUSIONS: Low HL and poor medication awareness are common in an academic neurology population. Sub-groups at increased odds of low HL included men, those with lower educational attainment, mild cognitive impairment, Medicaid/Medicare insurance, and stroke and epilepsy patients. Given the complexity of understanding required for adequate disease management, particular attention should be paid to improving overall HL.
Authors/Disclosures
Jori Fleisher, MD, MSCE, FAAN (Rush University Parkinson's and Movement Disorders Program)
PRESENTER 		The institution of Dr. Fleisher has received research support from Parkinson's Foundation. The institution of Dr. Fleisher has received research support from NIH/NINDS. The institution of Dr. Fleisher has received research support from NIH/NINDS. The institution of Dr. Fleisher has received research support from NIA/NINDS. The institution of Dr. Fleisher has received research support from NIA/NINDS. Dr. Fleisher has received publishing royalties from a publication relating to health care. Dr. Fleisher has received personal compensation in the range of $0-$499 for serving as a Speaker with Parkinson's Foundation. Dr. Fleisher has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Lewy Body Dementia Association. Dr. Fleisher has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Davis Phinney Foundation. Dr. Fleisher has a non-compensated relationship as a Editorial Board Member with AAN Brain & Life Magazine that is relevant to AAN interests or activities.
No disclosure on file
No disclosure on file
Nabila Dahodwala, MD, FAAN (Parkinson's disease and Movement Disorders Center) Dr. Dahodwala has received personal compensation in the range of $0-$499 for serving as a Consultant for Genetech. Dr. Dahodwala has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mediflix. Dr. Dahodwala has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Acadia. Dr. Dahodwala has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Post and Schell. Dr. Dahodwala has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for O'Brien & Ryan, LLP. Dr. Dahodwala has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for MotleyRice. The institution of Dr. Dahodwala has received research support from AbbVie. The institution of Dr. Dahodwala has received research support from Medtronic.
Robert Hyde, PhD (Biogen) Dr. Hyde has received personal compensation for serving as an employee of Biogen International GmbH . Dr. Hyde has received stock or an ownership interest from Biogen .